A Figueiredo

A Larsen

A Pantosti

A Simor

B Dhawan

D Blanc

F Layer

G Coombs

G Daikos

G Golding

H Kim

H Wang

J Conly

J Empel

J Etienne

J Lo

J Schrenzel

L Han

L Hoang

M Macedo-Vinas

M Mulvey

M Van Rijen

null null

P Francois

R Aschbacher

R Köck

R Skov

S Harbarth

T Maeda

T Saga

Z Zakaria

Antimicrobial Resistance and Infection Control

English

PubMed

Crossref

O036: Antibiotic resistance and molecular epidemiology of panton valentine leukocidin positive methicillin-resistant staphylococcus aureus (PVL+-MRSA): an international survey

Springer - Publisher Connector

ORAL PRESENTATION Open Access
O036: Antibiotic resistance and molecular
epidemiology of panton valentine leukocidin
positive methicillin-resistant staphylococcus
aureus (PVL+-MRSA): an international survey
M Macedo-Vinas*, J Conly, P Francois, R Aschbacher, D Blanc, G Coombs, G Daikos, B Dhawan, J Empel, J Etienne,
A Figueiredo, G Golding, L Han, L Hoang, H Kim, R Köck, A Larsen, F Layer, J Lo, T Maeda, M Mulvey, A Pantosti,
T Saga, J Schrenzel, A Simor, R Skov, M Van Rijen, H Wang, Z Zakaria, S Harbarth, PVL+-MRSA Global Survey
From 2nd International Conference on Prevention and Infection Control (ICPIC 2013)
Geneva, Switzerland. 25-28 June 2013
Introduction
PVL is usually associated with non multiresistant com-
munity-acquired MRSA. However, the epidemiology of
PVL+-MRSA is changing.
Objectives
We describe the resistance patterns and molecular epi-
demiology of PVL+-MRSA isolates from 17 countries
around the world.
Methods
Retrospective laboratory-based survey from 2008 to
2010. Participating countries (Australia, Brazil, Canada,
China, Denmark, France, Germany, Greece, Hong Kong,
India, Italy, Japan, Korea, Malaysia, Netherland, Poland,
Switzerland) reported on susceptibility to 10 non-beta-
lactam antibiotics and MLST and/or spa typing of PVL+
MRSA isolates. A selection of 49 isolates were analysed
by MLVA.
Results
Overall, susceptibility data of 3236 was reported. The
lowest susceptibility was observed for erythromycin in all
regions (17.3% in the Americas and 60% both in Europe
and Asia&Oceania). Vancomycin-intermediate isolates
were reported from Hong Kong and The Netherlands.
Multiresistance (3 or more non-beta-lactams) was
reported from all regions. Isolates belonged to 8 clonal
complexes. ST30 was reported worldwide, being the
most frequent type in Brazil and Asia. ST8 was the most
frequent in Canada. In Europe, ST80 and ST8 were both
reported in the first place. Six major clusters were discri-
minated by this method, showing a certain geographic
specificity and agreement with MLST.
Conclusion
PVL+-MRSA remains frequently susceptible to non-
beta-lactam agents, with in vitro activity of vancomycin,
rifampicin, cotrimoxazole and linezolid. However, multi-
resistant isolates were reported from all regions. Our
results are in agreement with recent observations that
suggest that USA300 and related clones are gradually
replacing the European ST80 clone. It is imperative to
continue monitoring susceptibility patterns and molecu-
lar epidemiology of MRSA to provide clinicians with the
most up-to-date information.
Disclosure of interest
M. Macedo-Vinas: None declared, J. Conly Grant/Research
support from Alberta Heritage Foundation for Medical
Research, the Canadian Institutes for Health Research and
Pfizer, Speaker’s Bureau of Janssen-Ortho and Pfizer, Con-
sultant for Canadian Agency for Drugs and Technologies
in Health , P. Francois: None declared, R. Aschbacher:
None declared, D. Blanc: None declared, G. Coombs:
None declared, G. Daikos: None declared, B. Dhawan:
None declared, J. Empel: None declared, J. Etienne: None
declared, A. Figueiredo: None declared, G. Golding: None
declared, L. Han: None declared, L. Hoang: None declared,
PVL+-MRSA Global Survey Study Group, Geneva, Switzerland
Macedo-Vinas et al. Antimicrobial Resistance and Infection Control 2013, 2(Suppl 1):O36
http://www.aricjournal.com/content/2/S1/O36
© 2013 Macedo-Vinas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
H. Kim: None declared, R. Köck: None declared, A. Larsen:
None declared, F. Layer: None declared, J. Lo: None
declared, T. Maeda: None declared, M. Mulvey: None
declared, A. Pantosti: None declared, T. Saga: None
declared, J. Schrenzel Consultant for bioMérieux, A. Simor
Grant/Research support from Pfizer Canada, Speaker’s
Bureau of Pfizer Canada, Novartis, and Sunovion, R. Skov:
None declared, M. Van Rijen: None declared, H. Wang:
None declared, Z. Zakaria: None declared, S. Harbarth
Grant/Research support from B. Braun, Pfizer and the
European Commission (MOSAR network contract LSHP-
CT-2007-037941), Speaker’s Bureau of bioMérieux and
Pfizer, Consultant for Destiny Pharma, DaVolterra and
bioMérieux.
Published: 20 June 2013
doi:10.1186/2047-2994-2-S1-O36
Cite this article as: Macedo-Vinas et al.: O036: Antibiotic resistance and
molecular epidemiology of panton valentine leukocidin positive
methicillin-resistant staphylococcus aureus (PVL+-MRSA):
an international survey. Antimicrobial Resistance and Infection Control 2013
2(Suppl 1):O36.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Macedo-Vinas et al. Antimicrobial Resistance and Infection Control 2013, 2(Suppl 1):O36
http://www.aricjournal.com/content/2/S1/O36
Page 2 of 2


https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-020-00847-x

O036: Antibiotic resistance and molecular epidemiology of panton valentine leukocidin positive methicillin-resistant staphylococcus aureus (PVL+-MRSA): an international survey

Abstract

Similar works

Full text

Available Versions

Crossref

Springer - Publisher Connector